Sunshine Biopharma Inc (SBFM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) has a cash flow conversion efficiency ratio of -0.070x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.62 Million) by net assets ($23.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Sunshine Biopharma Inc to measure how many days the company can operate on defensive assets alone.
Sunshine Biopharma Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Sunshine Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sunshine Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunshine Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wahana Inti MakmurTbk PT
JK:NASI
|
0.004x |
|
Manchester and London Investment Trust plc
LSE:MNL
|
-0.011x |
|
Sebata Holdings Ltd
JSE:SEB
|
0.031x |
|
London Security Plc
LSE:LSC
|
0.108x |
|
International Research Corporation Public Company Limited
BK:IRCP
|
0.071x |
|
Buff Technologies Ltd
TA:BUFT
|
1.599x |
|
VITAL BATTERY METALS INC
F:C0O
|
N/A |
|
Throgmorton Trust Plc
LSE:THRG
|
0.018x |
Annual Cash Flow Conversion Efficiency for Sunshine Biopharma Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Sunshine Biopharma Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Sunshine Biopharma Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $23.04 Million | $-5.33 Million | -0.231x | +56.60% |
| 2024-12-31 | $23.50 Million | $-12.53 Million | -0.533x | -28.87% |
| 2023-12-31 | $21.21 Million | $-8.78 Million | -0.414x | -70.51% |
| 2022-12-31 | $21.63 Million | $-5.25 Million | -0.243x | +97.19% |
| 2021-12-31 | $211.66K | $-1.83 Million | -8.642x | -1355.36% |
| 2020-12-31 | $-954.84K | $-657.30K | 0.688x | +2.10% |
| 2019-12-31 | $-735.38K | $-495.80K | 0.674x | -92.67% |
| 2018-12-31 | $-55.75K | $-512.81K | 9.198x | +870.28% |
| 2017-12-31 | $-573.36K | $-543.52K | 0.948x | -36.73% |
| 2016-12-31 | $-209.70K | $-314.18K | 1.498x | +3.10% |
| 2015-12-31 | $-597.04K | $-867.64K | 1.453x | +4.58% |
| 2014-12-31 | $-387.58K | $-538.60K | 1.390x | -98.10% |
| 2013-12-31 | $-7.71K | $-564.40K | 73.203x | +1411.63% |
| 2012-12-31 | $70.43K | $-393.05K | -5.581x | -93.36% |
| 2011-12-31 | $103.00K | $-297.30K | -2.886x | -62.59% |
| 2010-12-31 | $196.22K | $-348.32K | -1.775x | -1597.95% |
| 2009-12-31 | $97.80K | $-10.22K | -0.105x | -108.04% |
| 2008-12-31 | $-17.71K | $-23.03K | 1.301x | +658.01% |
| 2007-12-31 | $13.39K | $-3.12K | -0.233x | -- |
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also … Read more